The U.S. Department of Justice has withdrawn 16 pending rulemakings and 38 projected rules under President Trump's Executive Order 14192 ("Unleashing Prosperity Through Deregulation"), eliminating key Drug Enforcement Administration initiatives that have long delayed medical marijuana research and manufacturing approvals.
The sweeping deregulatory action removes several DEA proposals that companies have cited as procedural barriers to legitimate medical cannabis research, including Medical Marijuana and Cannabidiol Research Expansion (RIN 1117-AB83), Amendments to DEA Hearing Regulations (RIN 1117-AB50), Analytical Labs and Hemp regulations (RIN 1117-AB77), and Revision of Application for Manufacturing Quota (RIN 1117-AB86).
Seven-Year Regulatory Standoff Reaches Critical Juncture
MMJ BioPharma, which applied for DEA registration in 2018 to produce pharmaceutical-grade cannabis for FDA-authorized clinical trials, exemplifies the regulatory gridlock that has characterized medical marijuana research. The company secured FDA Orphan Drug Designations for both Huntington's disease (MMJ-002) and Multiple Sclerosis (MMJ-001) treatments, built a DEA-specification facility, and passed inspections, yet remains stalled by what company leadership describes as "administrative gamesmanship."
"This DOJ notice proves what we've said for years: the DEA kept MMJ and other companies in limbo by pointing to phantom rulemakings. Those rules will be withdrawn. There are no more excuses," said Duane Boise, President & CEO of MMJ BioPharma. "Administrator Terry Cole can approve our registration today under the Controlled Substances Act and let science move forward. The longer he waits, the more patients suffer."
Constitutional Challenges Compound Regulatory Uncertainty
The withdrawal of RIN 1117-AB50 addressing DEA hearing regulations carries particular significance following Supreme Court rulings in Axon v. FTC and Jarkesy v. SEC, which have raised constitutional questions about agency tribunal systems. With AB50 now off the agenda, the DEA cannot claim imminent reform of its in-house tribunals, leaving the current system both unreformed and constitutionally suspect.
The regulatory withdrawal creates both opportunities and challenges for medical marijuana research. While it removes DEA's shield of pending rulemaking that justified years of delays, it also signals no near-term regulatory relief from the agency itself, forcing decisions under existing law.
Immediate Implications for Medical Cannabis Research
With RIN 1117-AB83 (Medical Marijuana and CBD Research Expansion) withdrawn, the DEA will not implement the streamlined timelines, electronic processes, or supply safeguards many researchers anticipated. This places greater urgency on direct administrative decisions by DEA leadership and potential congressional or FDA oversight.
The action affects multiple companies beyond MMJ BioPharma, with industry sources indicating a pattern of unfair treatment, misrepresentations, and apparent intentional obstruction affecting registrants across the medical cannabis research sector.
Patient Populations Await Treatment Options
The regulatory delays have direct implications for patients with serious medical conditions. Huntington's disease is a progressive, fatal neurodegenerative disorder with no cure and limited symptomatic relief, while Multiple Sclerosis causes irreversible nerve damage and long-term disability. FDA-compliant cannabis medicines, such as MMJ's soft-gel formulations, could potentially address spasticity, pain, and neuroinflammation under rigorous clinical controls.
"This isn't about dispensaries or Big Weed - it's about real, prescription grade medicine," Boise said. "Congress passed the Research Expansion Act in 2022 for a reason. It's time for DEA to respect the law's intent and stop blocking clinical progress."
Path Forward Under Existing Framework
The withdrawal forces DEA Administrator Terry Cole to make decisions under current Controlled Substances Act provisions without the cover of pending rulemakings. Industry observers expect the agency to face increased pressure to approve compliant applications promptly and establish clear, consistent guidance under existing law.
MMJ BioPharma's pharmaceutical soft-gel capsules are manufactured to current Good Manufacturing Practice (cGMP) standards, and the company maintains international partnerships for botanical supply and European Union distribution while pursuing a fully compliant U.S. regulatory pathway.
